Editorial Comment to “Primary Resistance to Immune Checkpoint Inhibitor Combination Therapy in Metastatic Renal Cell Carcinoma: Focus on Nivolumab Plus Ipilimumab”

Enriched recordOpen access

Hiroshi Hirata

Abstract

No public abstract is available from the verified source records.

Authors

Institutions

No ROR-resolved institution is linked to this work yet.

Provenance

crossref

Confidence 100%

pubmed

Confidence 98%

europepmc

Confidence 96%

unpaywall

Confidence 95%

datacite

Confidence 0%

Referenced works

No local reference links have been materialized yet.

No local citing links have been materialized yet.

10.1111/iju.70597

10.1016/j.annonc.2026.02.017

10.1136/jitc‐2021‐004316

10.1016/s1470‐2045(22)00128‐0

10.1016/j.annonc.2026.02.011

No additional external references are available.